Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Wockhardt Q2 net loss...

    Wockhardt Q2 net loss widens to Rs 94 cr

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-11T13:11:48+05:30  |  Updated On 11 Nov 2019 1:11 PM IST
    Wockhardt Q2 net loss widens to Rs 94 cr

    New Delhi: Pharma major Wockhardt on Thursday reported widening of consolidated net loss to Rs 94.24 crore for the September quarter. The company had posted a consolidated net loss of Rs 30.84 crore in the same quarter last fiscal, Wockhardt said in a regulatory filing.


    Revenue from operations during the quarter declined to Rs 802.18 crore as compared to Rs 1,125.68 crore in the year-ago period. Revenue of India business, which accounted for 28 per cent of global sales, stood at Rs 227 crore in the second quarter as compared to Rs 455 crore in same period last fiscal.


    "The de-growth is mainly on account of lower sales in quality generics division and in some of the therapeutic areas," the company said. The US business clocked revenue of Rs 145 crore as compared to Rs 186 crore in the same period last fiscal, while emerging market sales were at Rs 132 crore as against Rs 144 crore in the same period last fiscal, the company added.


    Read Also: Wockhardt Q1 net loss shrinks to Rs 45 crore from previous fiscal loss of Rs 89.18 crore


    During the first half year ended September 30, 2019, Wockhardt said it has repaid Rs 408 crore towards various long-term debt obligations as per schedule. Subsequently, the total long-term outstanding debts as on September 30, 2019, is Rs 2,098 crore as compared to Rs 2,789 crore as on September 30, 2018, and Rs 2,469 crore as on March 31, 2019.


    Read Also: Wockhardt new antibiotics under development to have positive impact in future, says founder Khorakiwala

    fiscalpharmapharma companypharma newstherapeuticWockhardtWockhardt Q2 net loss
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok